Summit Therapeutics PLC (SMMT) Price Target Increased to $30.00 by Analysts at Needham & Company LLC
Summit Therapeutics PLC (NASDAQ:SMMT) had its target price lifted by Needham & Company LLC from $22.00 to $30.00 in a research report released on Tuesday morning. The firm currently has a buy rating on the stock.
Several other equities analysts also recently weighed in on the company. HC Wainwright began coverage on Summit Therapeutics PLC in a research report on Friday, September 16th. They set a buy rating and a $26.00 target price on the stock. Zacks Investment Research upgraded Summit Therapeutics PLC from a hold rating to a buy rating and set a $7.00 target price on the stock in a research report on Wednesday, September 14th. Canaccord Genuity reiterated a buy rating and set a $14.00 target price on shares of Summit Therapeutics PLC in a research report on Friday, September 9th. Janney Montgomery Scott began coverage on Summit Therapeutics PLC in a research report on Tuesday, June 21st. They set a buy rating on the stock. Finally, Oppenheimer Holdings Inc. reiterated a buy rating on shares of Summit Therapeutics PLC in a research report on Thursday, June 16th. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus price target of $21.00.
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded up 1.25% during trading on Tuesday, hitting $14.53. The stock had a trading volume of 271,205 shares. The company’s market cap is $178.63 million. The stock has a 50 day moving average of $7.48 and a 200 day moving average of $7.68. Summit Therapeutics PLC has a 12 month low of $4.26 and a 12 month high of $19.75.
An institutional investor recently raised its position in Summit Therapeutics PLC stock. AXA raised its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 382,705 shares of the company’s stock after buying an additional 5,500 shares during the period. AXA owned about 3.12% of Summit Therapeutics PLC worth $2,989,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 23.43% of the company’s stock.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.